Catholic Health Initiatives, Dignity Health exploring merger

Nonprofit health systems Catholic Health Initiatives (CHI) and Dignity Health have “signed a non-binding letter of intent” to merge, which could create one of the largest nonprofit hospital chains by revenue in the U.S.

The deal would combine Englewood, Colorado-based CHI’s 103 hospitals with San Francisco-based Dignity’s 39 hospitals, with the new system’s annual revenue reaching nearly $28 billion.

“The potential to align the strengths of these two organizations will allow us to play a far more significant role in transforming health care in this country," said CHI CEO Kevin E. Lofton. "Together, we could enhance our shared ministry as the health industry transitions to a system that rewards the quality and cost-effectiveness of care."

While CHI has facilities throughout most of the country, it doesn’t have a presence in California, Arizona or Nevada where Dignity operates, meaning there won’t be any geographical overlap of acute care facilities if the merger is completed. The two systems had already begun working together through the launch of a precision medicine program announced in September.

The Wall Street Journal reported CHI has been on shaky financial ground in recent years, partially thanks to its failed foray into health insurance and a number of hospital acquisitions. It reported $3.1 million in operating income in 2015 after a $109.4 million loss in 2014, according to the Journal.

The systems expect to continue merger talks into 2017.  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.